# Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder

> **NCT00432614** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 510 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** SR58611A
- **DRUG:** escitalopram
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00432614
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 510 (ACTUAL)
- **Last updated:** 2009-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00432614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00432614, "Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00432614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*